Isotretinoin and the risk of cardiovascular, cerebrovascular and thromboembolic disorders

Dermatology

Volumn 223, Issue 1, 2011, Pages 45-51

  Bérard, Anick ^a,b   Azoulay, Laurent ^c,d   Nakhai Pour, Hamid Reza ^a,b   Moussally, Krystel ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cardiovascular diseases; Cerebrovascular diseases; Isotretinoin; Myocardial infarction; Stroke; Thromboembolic disorders

Indexed keywords

ISOTRETINOIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CROSSOVER PROCEDURE; FEMALE; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHLEBITIS; PRESCRIPTION; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM; THROMBOPHLEBITIS;

ADULT; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; CROSS-OVER STUDIES; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; RISK; THROMBOEMBOLISM; YOUNG ADULT;

EID: 80053974376     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000330326     Document Type: Article

References (33)

1. Melnik BC: The role of transcription factor FoxO1 in the pathogenesis of acne vulgaris and the mode of isotretinoin action. G Ital Dermatol Venereol 2010; 145: 559-571.
2. Orfanos CE, Zouboulis CC: Oral retinoids in the treatment of seborrhoea and acne. Dermatology 1998; 196: 140-147. (Pubitemid 28116062)
3. Ellis CN, Krach KJ: Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001; 45:S150-S157. (Pubitemid 33032594)
4. Mitchell AA, Vanbennekom CM, Louik C: A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-106.
5. Azoulay L, Blais L, Koren G, LeLorier J, Berard A: Isotretinoin and the risk of depression in patients with acne vulgaris: a casecrossover study. J Clin Psychiatry 2008; 69: 526-532. (Pubitemid 351792326)
6. Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD: Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol 2010; 105: 1986-1993.
7. Springuel P, Roy G: Isotretinoin (Accutane): myocardial infarction, cerebrovascular and thromboembolic disorders. Can Adverse React Newsl 2006; 16: 3.
8. Hashimoto S, Koike T, Tatewaki W, Seki Y, Sato N, Azegami T, Tsukada N, Takahashi H, Kimura H, Ueno M, Arakawa M, Shibata A: Fatal thromboembolism in acute promyelocytic leukemia during all-trans-retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994; 8: 1113-1115. (Pubitemid 24224512)
9. Miyoshi T, Otsuki T, Omine K, Kirito K, Nagai T, Izumi T, Komatsu N, Madoiwa S, Mimuro J, Sakata Y, Ozawa K: Acute promyelocytic leukemia accompanied by retinoic acid syndrome with complications of acute myocardial infarction and cerebral infarction during treatment with all-trans-retinoic acid. Rinsho Ketsueki 2002; 43: 954-959.
10. Ciccone M, Rigolin GM, Viglione GM, Borrelli M, Serino ML, Cuneo A: Thrombosis of the cerebral veins and sinuses in acute promyelocytic leukemia after all-trans-retinoic acid treatment: a case report. Blood Coagul Fibrinolysis 2008; 19: 721-723.
11. Laroche ML, Macian-Montoro F, Merle L, Vallat JM: Cerebral ischemia probably related to isotretinoin. Ann Pharmacother 2007; 41: 1073-1076. (Pubitemid 46917640)
12. World Health Organization: International Classification of Diseases: 9th revision. Geneva, WHO, 1997.
13. Tamblyn R, Lavoie G, Petrella L, Monette J: The use of prescription claims databases in pharmacoepidemiologic research-the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009.
14. Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M: Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000; 53: 183-194. (Pubitemid 30151224)
15. Levy AR, Mayo NE, Grimard G: Rates of transcervical and pertrochanteric hip-fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 1995; 142: 428-436.
16. Blais L, Desgagne A, LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer-a nested case-control study. Arch Intern Med 2000; 160: 2363-2368.
17. Garbe E, LeLorier J, Boivin JF, Suissa S: Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997; 350: 979-982. (Pubitemid 27421106)
18. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, Lelorier J: Persistence of use of lipid-lowering medications-a crossnational study. JAMA 1998; 279: 1458-1462. (Pubitemid 28228203)
19. Berard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D: Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63: 196-205. (Pubitemid 46072106)
20. Maclure M: The case-crossover design-a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.
21. Azoulay L, Oraichi D, Berard A: Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol 2007; 157: 1240-1248. (Pubitemid 350115707)
22. Miller RA: Side effects of acne therapy and their management. J Cutan Med Surg 1998;2: 14-18.
23. Mercuro G, Deidda M, Piras A, Dessalvi CC, Maffei S, Rosano GMC: Gender determinants of cardiovascular risk factors and diseases. J Cardiovasc Med 2010; 11: 207-220.
24. Wull LL: Review of risk factors for cardivascular diseases. Ann Clin Lab Sci 1999; 29: 127-133.
25. Wilson V, Samuel B: Cerebrovascular disease. The Collaborative Neurology Book. 2010. http://knol.google.com/k/cerebrovascular-disease#.
26. Azoulay L, Oraichi D, Berard A: Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern? Eur J Clin Pharmacol 2006; 62: 667-674. (Pubitemid 44127997)
27. Prescrire rédaction: Attaque cérébrale et isotrétinoine? (Cerebral ischemia and isotretinoin). Rev Prescrire 2003; 23: 837.
28. Prescrire rédaction: Isotrétinoine: attaques cérébrales et infarctus? (Isotretinoin: stroke and myocardial infarction?) Rev Prescrire 2006; 26: 503.
29. Escudier SM, Kantarjian HM, Estey EH: Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans-retinoic acid. Leuk Lymphoma 1996; 20: 435-439. (Pubitemid 26096049)
30. Zane LT, Leyden WA, Marqueling AL, Manos M: A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142: 1016-1022. (Pubitemid 44268479)
31. Zech LA, Gross EG, Peck GL, Brewer HB: Changes in plasma-cholesterol and triglyceride levels after treatment with oral isotretinoin-a prospective study. Arch Dermatol 1983; 119: 987-993. (Pubitemid 14206942)
32. Georgala S, Schulpis KH, Potouridou I, Papadogeorgaki H: Effects of isotretinoin therapy on lipoprotein(a) serum levels. Int J Dermatol 1997; 36: 863-864. (Pubitemid 27521475)
33. Rafael C, Mario GP: Cholesterol, triglycerides, and associated lipoproteins; in Kenneth W, Dallas H, Willis H (eds): Clinical Methods: The History, Physical and Laboratory Examinations, ed 3, revised. Butterworth-Heinemann, 1990, pp 153-160.